Healthcare / BiotechnologyStockholm
$1.27
+0.00 (+0.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-65.8M · quality 42.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
6/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$108M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-358.1%
↓Gross Margin
N/A
•Debt/Equity
0.98
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.0%
FCF CAGR
—
FCF margin
-96.1%
FCF / Net income
0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $57.5M · net income $-110.0M · FCF $-55.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $57.5M | $57.5M | $94.6M | $5.7M | $61.1M |
| Net Income | $-110.0M | $-110.0M | $-83.1M | $-177.8M | $-113.4M |
| EBITDA | $-84.5M | $-84.5M | $-68.1M | $-173.3M | $-108.3M |
| EPS | -1.64 | -1.64 | -1.60 | -3.24 | -2.07 |
| Gross Margin | — | — | — | — | 100.0% |
| Operating Margin | -151.4% | -151.4% | -78.8% | -3183.6% | -185.2% |
| Net Margin | -191.4% | -191.4% | -87.8% | -3132.1% | -185.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.98 | 0.98 | 1.85 | 0.24 | 0.01 |
| Current Ratio | 0.88 | 0.88 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-55.2M | $-55.2M | $-65.8M | $-165.1M | $-146.0M |
| Returns | |||||
| ROE | -358.1% | -358.1% | -254.7% | -153.6% | -39.0% |
| Valuation | |||||
| P/B | 2.77 | 2.77 | 18.91 | 5.41 | 7.06 |
| Growth & Yield | |||||
| Revenue Growth | -39.3% | -39.3% | 1566.6% | -90.7% | — |
| EPS Growth | -2.5% | -2.5% | 50.6% | -56.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-83.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.60 → -1.64
Residual
-83.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.